DSpace at RU >

Browsing by Author Guchelaar, H.J.

Full Text	Issue Date	Title	Author(s)
	2011	Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer	Deenen, M.J.; Tol, J.; Burylo, A.M.; Doodeman, V.D.; Boer, A. de, et al
	2011	Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer	Pander, J.; Wessels, J.A.M.; Gelderblom, H.; Straaten, T. van der; Punt, C.J.A., et al
	2011	Pharmacogenetics: from bench to byte--an update of guidelines	Swen, J.J.; Nijenhuis, M.; Boer, A. de; Grandia, L.; Maitland-van der Zee, A.H., et al
	2010	Epidemiology of extracutaneous melanoma in the Netherlands.	Koomen, E.R.; Vries, E. de; Kempen, L.C.L.T. van; Akkooi, A.C. van; Guchelaar, H.J., et al
	2010	Regarding: 'Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array'.	Pander, J.; Gelderblom, H.; Straaten, T. van der; Punt, C.J.A.; Guchelaar, H.J.
	2010	Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.	Pander, J.; Gelderblom, H.; Antonini, N.F.; Tol, J.; Krieken, J.H.J.M. van, et al
	2010	Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial.	Arbouw, M.E.; Movig, K.L.L.; Koopmann, M.; Poels, P.J.E.; Guchelaar, H.J., et al
	2009	Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array.	Kweekel, D.M.; Antonini, N.F.; Nortier, J.W.; Punt, C.J.A.; Gelderblom, H., et al
	2009	Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.	Kweekel, D.M.; Gelderblom, H.; Antonini, N.F.; Straaten, T. van der; Nortier, J.W., et al
	2009	The Dutch vision of clinical pharmacology.	Schellens, J.H.; Grouls, R.; Guchelaar, H.J.; Touw, D.J.; Rongen, G.A.P.J.M., et al
	2009	Glycopyrroniumbromide for the treatment of sialorrhea in Parkinson's disease.	Arbouw, M.E.; Movig, K.L.L.; Koopmann, M.; Poels, P.J.E.; Guchelaar, H.J., et al
	2009	Pharmacogenetic determinants for discontinuation of non-ergoline dopamine agonists in Parkinson's disease.	Arbouw, M.E.; Movig, K.L.L.; Egberts, T.C.G.; Poels, P.J.E.; Vugt, J.P.P. van, et al
	2008	The Dutch model for clinical pharmacology: collaboration between physician- and pharmacist--clinical pharmacologists.	Schellens, J.H.M.; Grouls, R.; Guchelaar, H.J.; Touw, D.J.; Rongen, G.A.P.J.M., et al
	2008	GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.	Kweekel, D.M.; Koopman, M.; Antonini, N.F.; Straaten, T Van der; Nortier, J.W., et al
	2008	Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials.	Arbouw, M.E.; Movig, K.L.L.; Guchelaar, H.J.; Poels, P.J.P.; Vugt, J.P.A. van, et al
	2008	UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.	Kweekel, D.M.; Gelderblom, H.; Straaten, T Van der; Antonini, N.F.; Punt, C.J.A., et al
	2007	A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis.	Wessels, J.A.M.; Kooij, S.M. van der; Cessie, S. le; Kievit, W.; Barrera, P., et al
	2007	Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease.	Kooloos, W.M.; Jong, D.J. de; Huizinga, T.W.J.; Guchelaar, H.J.